The efficacy of hepatitis B vaccination among school age children in Southern Iran

Iranian Red Crescent Medical Journal

Volumn 12, Issue 1, 2010, Pages 45-48

  Hashemi, S A ^a   Moghadami, Mohsen ^a   Lankarani, K B ^a,b   Alborzi, A ^c   Mahbudi, A ^d  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Efficacy; Hepatitis B; Southern Iran; Vaccination

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IRAN; PREVALENCE; SCHOOL; SEROLOGY; STUDENT; VACCINATION;

EID: 73849139735     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107. [14996 343] [doi:10.1046/j.1365-2893.2003. 00487.x]
2. Daryani E. Heapatitis B Virulogy. Tabib Publication 2003; pp:69-145.
3. Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Noorinayer B, Derakhshan F, Chiani M, Rostami Nejad M, Antikchi MH, Sabahi F, Zali MR. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect 2008;14:858-66. [18844687] [doi:10. 1111/j.1469-0691.2008.02053.x]
4. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403. [121 27351] [doi:10.1016/S1473-3099 (02)00315-8]
5. Ayoola AE, Tobaigy MS, Gadour MO, Ahmad BS, Hamza MK, Ageel AM. The decline of hepatitis B viral infection in South-Western Saudi Arabia. Saudi Med J 2003;24:991-5. [12973485]
6. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187:134-8. [12508157] [doi:10.1086/345871]
7. Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, Parkinson AJ. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004 23:650-5. [15247604] [doi:10.1097/ 01.inf.0000130952.96259.fd]
8. Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population - a viral marker study. Ann Acad Med Singapore 1980;9:144-8. [7425524]
9. de Artaza Varasa T, Sánchez Ruano JJ, García Vela A, Gómez Rodríguez R, Romero Gutiérrez M, de la Cruz Pérez G, Gómez Moreno AZ, Carrobles Jiménez JM. Efficacy and safety of vaccination against hepatitis A and B in patients with chronic liver disease. Gastroenterol Hepatol 2009;32:483-8. [19577338]
10. Mele A, Tancredi F, Romanò L, Giuseppone A, Colucci M, Sangiuolo A, Lecce R, Adamo B, Tosti ME, Taliani G, Zanetti AR. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 2001;184:905-8. [11509998] [doi: 10.1086/323396]
11. Shih HH, Chang MH, Hsu HY, Lee PI, Ni YH, Chen DS. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatr Infect Dis J 1999;18:427-32. [10353515]
12. Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 1999;29:924-7. [10051499] [doi:10.1002/hep.5102 90327]
13. Boxall EH, A Sira J, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004;190:1264-9. [15346336] [doi: 10.1086/423818]
14. Zali MR, Mohammad K, Farhadi A, Masjedi MR, Zargar A, Nowroozi A. Epidemiology of hepatitis B in the Islamic Republic of Iran. East Mediterr Health J 1996;2:290-298
15. Hadler SC, Coleman PJ, O'Malley P, Judson FN, Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: F.B. Hollinger, Lemon SM, Margolis HS, Editors, Viral hepatitis and liver disease. Williams & Wilkins, Baltimore 1991; pp.766-768.
16. García Llop L, Asensi Alcoverro A, Coll Más P, Ramada Benedito MA, Grafiá Juan C. Anti-HBs titers after a vaccination program in children and adolescents. Should a booster dose be given? An Esp Pediatr 2001;54:32-7. [11181192]
17. van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One 2007; 2:e753. [17710 152] [doi:10.1371/journal. pone.00 00753]
18. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 2006; 193:1528-35.